Clinical Trials Logo

Triple Negative Breast Neoplasms clinical trials

View clinical trials related to Triple Negative Breast Neoplasms.

Filter by:
  • Recruiting  
  • « Prev · Page 30

NCT ID: NCT01514565 Recruiting - Breast Cancer Clinical Trials

Tumor Suppressor Status as a Predictor of Chemotherapy Response in Triple Negative Breast Cancer

Start date: December 2011
Phase: N/A
Study type: Observational

This is a prospective observational study aimed to validate biomarkers that predict response.

NCT ID: NCT01378533 Recruiting - Breast Cancer Clinical Trials

The Trial Comparing Dose-dense AC-T With PC as Adjuvant Therapy for TNBC

Start date: May 2011
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to compare the 3 years DFS of dose-dense epirubicin and cyclophosphamide followed by paclitaxel with paclitaxel plus carboplatin as adjuvant therapy for triple-negative breast cancer. The other purpose of this trial is to observe the patient's tolerance.

NCT ID: NCT01276769 Recruiting - Clinical trials for Triple Negative Breast Cancer

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This study is to compare the effective of Paclitaxel combined with Epirubicin and Paclitaxel plus Carboplatin in the neoadjuvant treatment for TNBC. And the investigators hypothesized that paclitaxel combined with carboplatin is more sensitive to TNBC compared with Paclitaxel plus Epirubicin,this study will also have a look into the relation of BRCA1 mutation and sensitive to carboplatin.

NCT ID: NCT01042379 Recruiting - Breast Cancer Clinical Trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

I-SPY
Start date: March 1, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.